<DOC>
	<DOC>NCT00175435</DOC>
	<brief_summary>This study will look at what happens to the level of protection against hepatitis B (HB) disease if a 'helper' gel is applied to the skin over the injection site of a small dose of hepatitis B vaccine.</brief_summary>
	<brief_title>Optimizing Hepatitis B Vaccine Response Through the Use of a Topical Immune Modulator</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunologic Factors</mesh_term>
	<criteria>Previously vaccinated with conventional hepatitis B vaccine series 10 or more years ago Generally healthy Is and has been free of HB disease and/or is negative to core antibody Known to have seroconverted to positive after vaccine series (without extra doses) Speaks and understands English adequately Available for all 4 visits within the designated timelines (30 days) No allergies to HB vaccine or components No blood or blood components within previous 6 months Not pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Topical Immune Modulator</keyword>
	<keyword>resiquimod gel</keyword>
	<keyword>Hepatitis B booster response</keyword>
	<keyword>Vaccine Evaluation</keyword>
	<keyword>Prevention of Hepatitis B disease</keyword>
</DOC>